4/A//SEC Filing
Currie Graeme Martin 4/A
Accession 0001213900-24-030959
CIK 0001841330other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 9:45 PM ET
Size
6.2 KB
Accession
0001213900-24-030959
Insider Transaction Report
Form 4/AAmended
Currie Graeme Martin
Chief Development Officer
Transactions
- Award
Stock Option (right to buy)
2024-03-01+5,938→ 5,938 totalExercise: $8.13Exp: 2034-02-28→ Common Stock (5,938 underlying)
Footnotes (2)
- [F1]The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
- [F2]The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024.
Documents
Issuer
Pasithea Therapeutics Corp.
CIK 0001841330
Entity typeother
Related Parties
1- filerCIK 0001965006
Filing Metadata
- Form type
- 4/A
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 9:45 PM ET
- Size
- 6.2 KB